Jonas Bergh

70.3k total citations · 14 hit papers
521 papers, 29.1k citations indexed

About

Jonas Bergh is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Jonas Bergh has authored 521 papers receiving a total of 29.1k indexed citations (citations by other indexed papers that have themselves been cited), including 337 papers in Oncology, 232 papers in Cancer Research and 136 papers in Molecular Biology. Recurrent topics in Jonas Bergh's work include Breast Cancer Treatment Studies (168 papers), HER2/EGFR in Cancer Research (93 papers) and Cancer Treatment and Pharmacology (86 papers). Jonas Bergh is often cited by papers focused on Breast Cancer Treatment Studies (168 papers), HER2/EGFR in Cancer Research (93 papers) and Cancer Treatment and Pharmacology (86 papers). Jonas Bergh collaborates with scholars based in Sweden, United States and United Kingdom. Jonas Bergh's co-authors include Lars Holmberg, Hans Nordgren, Johanna Smeds, Mauro Delorenzi, Martine Piccart, Lance D. Miller, Per Hall, Yudi Pawitan, Christos Sotiriou and Fátima Cardoso and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jonas Bergh

510 papers receiving 28.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

2006 1.5k citations Christos Sotiriou, Johanna Smeds et al. profile →
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

2017 1.1k citations Jonas Bergh et al. profile →
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

2005 966 citations Lance D. Miller, Johanna Smeds et al. Proceedings of the National Academy of Sciences profile →
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

2006 842 citations Jonas Bergh, Christos Sotiriou et al. profile →
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

2007 726 citations Jonas Bergh, John A. Foekens et al. Clinical Cancer Research profile →
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

2005 613 citations Yudi Pawitan, Per Hall et al. profile →
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

2007 599 citations Jonas Bergh, John A. Foekens et al. profile →
Identification of molecular apocrine breast tumours by microarray analysis

2005 585 citations Jonas Bergh et al. profile →
Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing

2018 561 citations Michael Bartoschek, Nikolay Oskolkov et al. Nature Communications profile →
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer

2006 543 citations Anna V. Ivshina, Joshy George et al. Cancer Research profile →
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials

2017 536 citations Jonas Bergh et al. profile →
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

2015 473 citations Jonas Bergh profile →
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

2017 408 citations Helene Rundqvist, Thomas Hatschek et al. profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Jonas Bergh

Since Specialization

Citations

This map shows the geographic impact of Jonas Bergh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Bergh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Bergh more than expected).

Fields of papers citing papers by Jonas Bergh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Bergh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Bergh. The network helps show where Jonas Bergh may publish in the future.

Co-authorship network of co-authors of Jonas Bergh

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Bergh. A scholar is included among the top collaborators of Jonas Bergh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Bergh. Jonas Bergh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 breakdown → 2024 ·Annals of Oncology ·Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, Javier Cortés, Rebecca Dent, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Ying Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid	47
2	339TiP A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE) 2024 ·Annals of Oncology ·(unknown), (unknown), Andreas Karakatsanis, Anne Andersson, (unknown), (unknown), Zakaria Einbeigi, (unknown), Fredrika Killander, Barbro Linderholm, (unknown), Antonios Valachis, Jonas Bergh, Guillermo Villacampa, (unknown), Mats Hellström, (unknown), Alexios Matikas	1
3	Five-year follow-up of the OptiTrain trial on concurrent resistance and high-intensity interval training during chemotherapy for patients with breast cancer 2024 ·Scientific Reports ·Poorna Anandavadivelan, Sara Mijwel, Maria Wiklander, (unknown), (unknown), Jonas Bergh, Helene Rundqvist, Yvonne Wengström	4
4	Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications 2023 ·EJNMMI Research ·Renske Altena, Antonios Tzortzakakis, (unknown), Thuy Tran, Fredrik Y. Frejd, Jonas Bergh, Rimma Axelsson	8
5	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial 2021 ·Clinical Cancer Research ·Carina Strell, (unknown), Erik Holmberg, (unknown), (unknown), Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Wärnberg, Arne Östman	10
6	Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data 2019 ·Clinical Cancer Research ·Alexios Matikas, Ioannis Zerdes, John Lövrot, François Richard, Christos Sotiriou, Jonas Bergh, Antonios Valachis, Theodoros Foukakis	73
7	Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing breakdown → 2018 ·Nature Communications ·Michael Bartoschek, Nikolay Oskolkov, Matteo Bocci, John Lövrot, Christer Larsson, Mikael N.E. Sommarin, Chris D. Madsen, David Lindgren, Gyula Pekár, Göran Karlsson, Markus Ringnér, Jonas Bergh, Åsa K. Björklund, Kristian Pietras	561
8	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients 2017 ·Clinical Cancer Research ·Nicholas P. Tobin, Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Theodoros Foukakis, Lena Carlsson, Zakaria Einbeigi, Barbro Linderholm, Niklas Loman, Martin Malmberg, Mårten Fernö, Kamila Czene, Charles M. Perou, Jonas Bergh, Thomas Hatschek	10
9	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts 2017 ·Clinical Cancer Research ·Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Claudette Falato, Joseph W. Carlson, Paul K. Wright, Theodoros Foukakis, Charles M. Perou, Kamila Czene, Jonas Bergh, Nicholas P. Tobin	34
10	EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma 2017 ·The Oncologist ·Kyriaki Tzogani, Paula B. van Hennik, (unknown), (unknown), (unknown), Jan Sjöberg, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti	31
11	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes 2016 ·Clinical Cancer Research ·Jingmei Li, Emma Ivansson, Daniel Klevebring, Nicholas P. Tobin, Linda S. Lindström, Johanna Holm, (unknown), (unknown), Juni Palmgren, Sven Törnberg, Keith Humphreys, Johan Hartman, Jan Frisell, Mattias Rantalainen, Johan Lindberg, Per Hall, Jonas Bergh, Henrik Grönberg, Kamila Czene	15
12	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors 2016 ·Clinical Cancer Research ·Nicholas P. Tobin, Kristian Wennmalm, Linda S. Lindström, Theodoros Foukakis, Liqun He, Guillem Genové, Arne Östman, Göran Landberg, Christer Betsholtz, Jonas Bergh	7
13	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages 2016 ·Cancer Research ·(unknown), (unknown), Margarita Bartish, Jeanette Östling, Artur Mezheyeuski, Nicholas P. Tobin, (unknown), (unknown), Paola Pellegrini, Mario Leonardo Squadrito, Fredrik Pontén, Johan Hartman, Jonas Bergh, Angelo De Milito, Michele De Palma, Arne Östman, John Andersson, Charlotte Rolny	46
14	Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients 2016 ·Clinical Cancer Research ·Judith S. Brand, Elham Hedayati, Keith Humphreys, Jonas F. Ludvigsson, Anna L.V. Johansson, Jonas Bergh, Per Hall, Kamila Czene	11
15	Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer 2015 ·Cancer Research ·Sara I. Cunha, Matteo Bocci, John Lövrot, (unknown), Pernilla Roswall, Eugenia Cordero, Linda S. Lindström, Michael Bartoschek, Kristian Hallermalm, R. Scott Pearsall, Aaron W. Mulivor, Ravindra Kumar, Christer Larsson, Jonas Bergh, Kristian Pietras	48
16	Validation of a Radiosensitivity Molecular Signature in Breast Cancer 2012 ·Clinical Cancer Research ·Steven A. Eschrich, William J. Fulp, Yudi Pawitan, John A. Foekens, Marcel Smid, John W.M. Martens, Michelle Echevarria, Vidya Kamath, Ji‐Hyun Lee, Eleanor Harris, Jonas Bergh, Javier F. Torres–Roca	145
17	An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer 2011 ·Cancer Research ·Lance D. Miller, Lan Coffman, Jeff W. Chou, Michael A. Black, Jonas Bergh, Ralph B. D’Agostino, Suzy V. Torti, Frank M. Torti	169
18	Gene Expression Preferentially Regulated by Tamoxifen in Breast Cancer Cells and Correlations with Clinical Outcome 2006 ·Cancer Research ·Jonna Frasor, Edmund C. Chang, Barry S. Komm, Chin‐Yo Lin, Vinsensius B. Vega, Edison T. Liu, Lance D. Miller, Johanna Smeds, Jonas Bergh, Benita S. Katzenellenbogen	137
19	Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer breakdown → 2006 ·Cancer Research ·Anna V. Ivshina, Joshy George, O. V. Sen’ko, Benjamin Mow, Thomas Choudary Putti, Johanna Smeds, Thomas Lindahl, Yudi Pawitan, Per Hall, Hans Nordgren, John E.L. Wong, Edison T. Liu, Jonas Bergh, Vladimir A. Kuznetsov, Lance D. Miller	543
20	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival breakdown → 2005 ·Proceedings of the National Academy of Sciences ·Lance D. Miller, Johanna Smeds, Joshy George, Vinsensius B. Vega, Liza A. Vergara, Alexander Ploner, Yudi Pawitan, Per Hall, Sigrid Klaar, Edison T. Liu, Jonas Bergh	966

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact